Trunerox 10% CBD Formula
Avicanna’s first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
Trunerox™ – 10% CBD (100 mg/ml Cannabidiol)
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence
Pharmaceutical preparation under GMP standards with completed technical dossier
Expected marketing authorization durign 2022 in Colombia, Ecuador, Argentina, Mexico and Brazil
Utilizing Avicanna’s proprietary formulations and vertical integration to deliver a pharmaceutical CBD preparation with affordable pricing into the Latin American Markets.